DENTSPLY SIRONA stock
XRAYNASDAQDENTSPLY SIRONA Inc., HealthcareISIN US24906P1093
48Score 48 out of 100, Weak
Price and trend
58 / 100
Price history
−15% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 18% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 48).
The price is 37% below its 52-week high. Largest decline in 20 years: 88% (May 2021 to October 2026).
Chart figures for advanced users
- SMA 50$9.48
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$11.21
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)48
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$8.42
- The lowest closing price of the last twelve months.
- Resistance$14.68
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- DENTSPLY SIRONA Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $1.84B, is number 34 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $3.68B (down 3% year on year) and a loss of $598M.
- For fiscal 2026, analysts expect on average revenue of $3.57B (down 3%) and adjusted earnings per share of $1.52 (down 4.5%).
Show more
- MEQIRI Score 48 out of 100 (Weak): rank 415 of 714 in Healthcare, median 53.
- Our model puts fair value at $12.29, with the price 21% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Share buybacksShare count down 9% since 2020.Capital allocation 57
Weaknesses
- Loss-makingLoss of $121M over the last 12 months.Fundamentals 52
- High debtDebt 1.69 times equity (latest quarter), Medical (Instruments & Supplies) median 0.45.Stability 39
- Volatile share priceVolatility 48% a year over the last 12 months.Stability 39
Its standout strength is valuation, while profitability and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 47 to 48.
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- high price swings
- weak fundamentals
Valuation
Valuation signal
Modestly undervaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $8.78 and expensive above $20.48 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 10.5%. At 11.5% the fair value would be $10.69, at 9.5% it would be $14.46.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 1.4% on the twelve months before. Revenue has grown solidly since 2006, at about 4% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 50%, operating 7%, net −16%. Last 12 months: net −3%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported $0.29 (expected $0.31)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.52−0.7%
- Revenue
- $3.57B−0.1%
- Earnings per share
- $1.47−1.8%
- Revenue
- $3.61B−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −12.0%2026 outlook maintained: net sales of $3.5 billion to $3.6 billion, adjusted EPS of $1.40 to $1.50 (excluding tariff refunds).
“We are maintaining our 2026 outlook for net sales of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50 This EPS range excludes the benefit from tariff refunds and impact of incremental tariffs.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
6 insiders bought on the open market between 11 Jun 2026 and 15 Jun 2026, $617,199 in total.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at DENTSPLY SIRONA
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 48
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- AtriCureATRC $2.93B53
- AddLifeALIF-B.ST $2.17B59
- AzentaAZTA $2.14B52
- Bonesupport HoldingBONEX.ST $2.1B72
- Kestra Medical TechnologiesKMTS $1.88B45
- SKAN GroupSKAN.SW $1.88B72
- LeMaitre VascularLMAT $1.81B70
- STAAR SurgicalSTAA $1.34B45
ETFs that hold DENTSPLY SIRONA
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.08% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.07% | 0.30% | €4.22B |
Show 5 more
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.06% | 0.30% | €944.34M |
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.06% | 0.30% | €5.27B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2022)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.